The Riverside Company has made an investment in Belgium-based Alter Pharma, a provider of pharmaceutical products to wholesale pharmacies and hospitals. No financial terms were disclosed. Allen & Overy, Ernst & Young, IQVIA, Alix Partners and NDA Group advised Riverside on the deal while Jefferies International Ltd acted as financial adviser to Alter Pharma.
The Riverside Company has invested in Alter Pharma, a Belgian pharmaceutical group.
Alter Pharma distributes EU-sourced pharmaceutical products to wholesalers pharmacies and hospitals. It also develops and reformulates generic pharmaceuticals using GMP approved third-party manufacturers, and sells them internationally through partnerships.
“Alter Pharma is a very innovative company, led by an excellent management team skilled at spotting opportunities and developing products to meet customer needs and capture market share,” said Riverside Partner Karsten Langer. “It offers tremendous value thanks to a diversified and growing line of more than 100 products backed by a robust pipeline of product launches planned for coming years.”
Alter Pharma’s products serve a wide range of therapeutic areas, including oncology, gastroenterology, pain, cardiology, neurology and others to follow.
Riverside is partnering with Alter Pharma to accelerate the company’s growth.
“We are delighted to be teaming up with Riverside to achieve our shared vision for Alter Pharma,” said Stijn Van Rompay, Alter Pharma’s founder and CEO. “Their experience in our industry and global connections should accelerate growth and help us reach even more customers.”
Riverside has completed more than 100 investments in its Healthcare specialization, and will use its global resources to help Alter Pharma to expand the company’s footprint, develop new products and increase market share.
Working with Langer on the transaction for Riverside were Principal Damien Gaudin and Associate Gaspard d’Avout d’Auerstaedt.
Belfius Bank, ING Belgium and NIBC Bank provided financing for the transaction. Allen & Overy, Ernst & Young, IQVIA, Alix Partners and NDA Group advised Riverside on the deal. Jefferies International Ltd acted as exclusive financial adviser to Alter Pharma. Eubelius is serving as legal counsel to Alter Pharma.
About The Riverside Company
The Riverside Company is a global private equity firm focused on acquiring and investing in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has invested in more than 490 transactions. The firm’s international portfolio includes more than 80 companies.